Otsuka Holdings Co., Ltd.: Alzheimer Disease trials
The registry lists 21 Alzheimer Disease studies with Otsuka Holdings Co., Ltd. as lead sponsor. 1 are open to participants now and 12 have results posted.
Phase 2 2Phase 3 17No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's DementiaRecruitingNCT06875986
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedNCT04464564Phase 3Results posted
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeTerminatedNCT04408755Phase 3Results posted
- Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeCompletedNCT03724942Phase 3Results posted
- Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeCompletedNCT03620981Phase 2/3Results posted
- A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeCompletedNCT03594123Phase 3Results posted
- A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's TypeCompletedNCT03548584Phase 3Results posted
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's TypeCompletedNCT02442778Phase 3Results posted
- Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeCompletedNCT02442765Phase 3Results posted
- Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeCompletedNCT01922258Phase 3Results posted
- A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's AgitationCompletedNCT01862640Phase 3Results posted
- Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's DiseaseCompletedNCT01584440Phase 2Results posted
- Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's TypeCompletedNCT01438060Phase 3Results posted
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeCompletedNCT03393520Phase 3
- Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or PlaceboCompletedNCT02192554
- Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's TypeTerminatedNCT02168920Phase 3
- PRISM Registry: Pseudobulbar Affect Registry SeriesCompletedNCT01366027
- Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With DementiaCompletedNCT00095719Phase 3
- Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)CompletedNCT00056524Phase 3
- Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCompletedNCT00041678Phase 3
- Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeCompletedNCT00036114Phase 3